Involvement of Plasmatic Factors in the Peripheral Muscle Dysfunction of COPD Patients - In Vitro Study

N/ACompletedNCT03197909

University Hospital, Montpellier18 enrolled

Overview

Chronic Obstructive Pulmonary Patients is a defined by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. It is associated with an atrophy of the skeletal muscle that impairs the patient's prognosis. The biological mechanisms of this muscle atrophy have not been elucidated, and the "spill-over theory" has recently emerged. Indeed, in COPD patients, the pulmonary inflammation is associated with a systemic low-grade inflammation, and the increased pro-inflamatory molelcules in the blood - which constitute the cellular micro-environement of the muscle fibre - could activate the mechanisms of the cell atrophy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chronic Obstructive Pulmonary

Interventions

Determination of pro-inflammatory plasma factorsOTHER

Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old

Eligibility

Sex: ALLMin age: 35 YearsMax age: 85 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 35 to 85 years old * COPD patients: association of symtoms (breathlessness, cough, sputum) and chronic exposure to inhalated risk factors (like tobacco smoke) and a FEV1/VC ratio \<70% assessed by a spirometry * Healthy subjects: A sedentariness assessed by a Voorrips score \<9.4 and/or a report of \<150 min/week of moderate-to-vigorous physical activity Exclusion Criteria: * A recent COPD exacerbation (\< 4weeks) * The decompensation of a comorbidity * An antioxidant supplementation or medication * A long-term systemic corticosteroid medication

Outcomes

Primary Outcomes

Myotube diameter of in vitro cultured myotubes

Myotube diameter of in vitro cultured myotubes from healthy subjects, exposed to the serum of healthy controls and COPD patients

Time frame: 6 days

Secondary Outcomes

Expression and translation of markers of

Expression and translation of markers of anabolic and catabolic pathways